| | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular . . . |
Terminated |
03 Feb 2022 |
| | A randomized double-masked, phase III study assessing ranibizumab intravitreal injections versus sham control in patients with visual impairment due to macular edema (ME) secondary to branch retinal v . . . |
Completed |
25 Jan 2022 |
| | A randomized double-masked, phase III study assessing ranibizumab intravitreal injections versus sham control in patients with visual impairment due to macular edema (ME) secondary to central retinal . . . |
Completed |
25 Jan 2022 |
| | A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephr . . . |
Completed |
02 Mar 2020 |
| | A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis . . . |
Completed |
22 Mar 2022 |
| | A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter . . . |
Ongoing |
25 May 2022 |
| | A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabe . . . |
Completed |
23 Sep 2019 |
| | A Randomized, Double-Blind, International Multi-Center Clinical Study to Investigate Efficacy and Safety of Lianhua Qingwen Capsules Compared to Placebo and Combined with Standard of Care (SOC) in Adu . . . |
Ongoing |
30 Nov -0001 |
| | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients wi . . . |
Ongoing |
03 Jul 2020 |
| | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient . . . |
Ongoing |
30 Mar 2021 |
| | A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient . . . |
Ongoing |
31 Mar 2021 |
| | A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturn . . . |
Pending |
24 Nov 2021 |
| | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects with Guillain Barré Syndrome (GBS) . . . |
Ongoing |
23 Mar 2022 |
| | A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease . . . |
Pending |
30 Nov -0001 |
| | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in Asian subjects (≥16 to 80 years of age) with parti . . . |
Ongoing |
01 Apr 2022 |
| | A randomized, double-blind, placebo-controlled, parallel group, multi-center trial of pregabalin as adjunctive therapy in pediatric and adult subjects with primary generalized tonic-clonic seizures . . . |
Completed |
17 Jul 2019 |
| | A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as Add on to Standard of Care in Adult Subjects With COVID-19 . . . |
Ongoing |
30 Nov -0001 |
| | A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerabilit . . . |
Ongoing |
30 Jul 2020 |
| | A Randomized, Double-blind, Placebo-controlled, Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetic Profiles and Immunogenicity of JS016 (Recombinant Human Anti-SA . . . |
Completed |
22 Apr 2022 |
| | A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined with Chemotherapy versus Placebo with Chemotherapy . . . |
Terminated |
19 Jul 2021 |
| | A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic L . . . |
Pending |
12 May 2020 |
| | A randomized, observer blinded, controlled trial to evaluate the safety and immunogenicity of a new formulation of Euvichol® (killed bivalent (O1 and O139) whole cell oral cholera vaccine (WC-OCV) ma . . . |
Completed |
22 Apr 2019 |
| | A Randomized, Observer-blind, Phase 2/3 Adaptive Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in . . . |
Terminated |
04 May 2022 |
| | A Randomized, Open Label Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) versus Intravenous Methotrexate in Patients with Recurrent and/or Metastatic Head and Neck Squ . . . |
Completed |
01 Jul 2019 |
| | A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx®) 300 mg administered subcutaneously in pat . . . |
Pending |
30 Nov -0001 |